Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–60 of 546 records
Insulin glargine (Lantus)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Once-daily background insulin for type 1 and type 2 diabetes
Etanercept (Enbrel)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Rheumatoid arthritis, psoriasis and related long-term inflammatory diseases
Insulin Aspart (NovoLog / Fiasp / NovoLog Mix 70/30 / Kirsty / Merilog / Garzulys)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Diabetes — the fast insulin taken around meals
Epoetin alfa (Epogen / Procrit)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Low red blood cell count caused by kidney failure, HIV treatment or chemotherapy
Alteplase (Activase / Cathflo Activase)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Emergency clot-dissolving treatment for stroke, heart attack and major pulmonary embolism
Insulin Degludec (Tresiba)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Diabetes — the once-daily background insulin that lasts over 42 hours
Peginterferon Alfa-2a (Pegasys)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Long-standing hepatitis B or hepatitis C, treated by stimulating the immune system rather than by attacking the virus directly
Insulin Detemir (Levemir)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Diabetes — the background insulin that works through the day
Insulin lispro (Humalog)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Fast-acting mealtime insulin for type 1 and type 2 diabetes
Somatropin (Humatrope)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Children who are not growing normally, and adults with a damaged pituitary gland
Aflibercept (Eylea)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Leaking abnormal blood vessels at the back of the eye, in macular degeneration and in diabetes
Andexanet Alfa (Andexxa)
Protein medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Detailed recordUse listed on the medicine record
Switching off apixaban or rivaroxaban when someone on one of them has a bleed that will not stop
Filgrastim (Neupogen)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Rebuilding infection-fighting white cells knocked down by chemotherapy
Follistatin-344 (FS344; delivered in trials as AAV1.CMV.huFollistatin344. Sold online as "Follistatin 344" lyophilised powder)
Protein medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Blocks the brake on muscle growth — a gene therapy in trials, sold online as an injection
Fibrinogen Concentrate (Human) (Riastap / Fibryga)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Replacing the protein that clots are actually made of, in people born without enough of it
Romiplostim (Nplate)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
A weekly injection that tells the bone marrow to make more platelets — and, separately, the drug stockpiled to keep people alive after a radiation accident
Pegfilgrastim (Neulasta)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
One injection per chemotherapy cycle instead of a daily white cell injection
Protamine Sulfate
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Switching off heparin when someone has had too much of it, or when the operation using it has finished
Recombinant Factor VIIa (NovoSeven RT / Sevenfact)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Stopping bleeding in people with haemophilia whose bodies have learned to destroy the replacement clotting factor they used to be given
Four-Factor Prothrombin Complex Concentrate (Kcentra / Beriplex / Confidex; Octaplex and Balfaxar are separate products)
Protein medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Putting back the clotting proteins that warfarin has switched off, in someone who is bleeding badly or needs surgery within hours
Abatacept (Orencia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Anakinra (Kineret)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Neonatal-Onset Multisystem Inflammatory Disease
Beta Glucanase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordBeta-Glucosidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordFollitropin (Follistim Aq / Gonal-F Rff Redi-Ject)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
FOLLISTIM ® AQ Cartridge (follitropin beta) injection, is indicated: In Women for: FOLLISTIM AQ Cartridge is a gonadotropin indicated: In Women for: Induction of Ovulation and Pregnancy in Anovulatory Infertile Women in Whom the Cause of Infertility is Functional and Not Due to Primary Ovarian Failure ( 1.1 ) Pregnancy in Normal Ovulatory Women Undergoing Controlled Ovarian Stimulation as Part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) Cycle ( 1.2 ) In Men for: Induction of Spermatogenesis in Men with Primary and Secondary Hypogonadotropic Hypogonadism (HH)…
Aflibercept-Abzv (Enzeevu)
Protein medicineApproved in the United States (FDA)Expanded recordBelatacept (Nulojix)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Prophylaxis of organ rejection
Catkin
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHuman Vaccinia Virus Immune Globulin (Cnj-016)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Complications due to vaccinia vaccination ( 1 ), including
Insulin Human (Humulin R / Novolin 70/30 / Afrezza / Myxredlin / Novolin N / Humulin R U-500)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Glycemic control
4-Phytase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordAdalimumab-Ryvk (Simlandi)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. ( 1.1 ) Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Catalase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordCertolizumab pegol (Cimzia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Conestat alfa (Ruconest)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Acute attacks
Human Peripheral Nerve Tissue (Avance Nerve Graft)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Adult and pediatric patients aged one month and older
Insulin Aspart-Szjj (Merilog)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Lispro-Aabc (Lyumjev)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Pbbk (Fylnetra)
Protein medicineApproved in the United States (FDA)Expanded recordAcellular Tissue Engineered Vessel (Symvess)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
As a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein
Adalimumab-Adaz (Hyrimoz)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Adbm (Cyltezo)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Atto (Amjevita)
Protein medicineApproved in the United States (FDA)Expanded recordAflibercept-Mrbb (Ahzantive)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD)…
Agalsidase beta (Fabrazyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Albumin Aggregated (Pulmotech Maa / Draximage Maa)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adult patients. DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is a radioactive diagnostic agent indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.
Bordetella Pertussis Filamentous Hemagglutinin Antigen (Boostrix / Pediarix / Daptacel / Quadracel / Kinrix / Vaxelis)
Protein medicineLaboratory or animal-stage researchExpanded recordDenosumab-Kyqq (Aukelso / Bosaya)
Protein medicineApproved in the United States (FDA)Expanded recordGemtuzumab Ozogamicin (Mylotarg)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Newly-diagnosed CD33-positive acute myeloid leukemia
Human Botulinum Neurotoxin A/B Immune Globulin (Babybig)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Infant botulism caused by toxin type A or B
Human Rotavirus A Type G4p7 Strain Brb Live Antigen (Rotateq)
Protein medicineLaboratory or animal-stage researchExpanded recordPegvisomant (Somavert)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acromegaly
Prolase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordSummer Flounder (Flounder)
Protein medicineLaboratory or animal-stage researchExpanded recordTaliglucerase alfa (Elelyso)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease
Tividenofusp alfa (Avlayah)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
AVLAYAH is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. This indication is approved under accelerated approval based on the reduction of cerebrospinal fluid heparan sulfate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Adalimumab-Afzb (Abrilada)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Bwwd (Hadlima)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Fkjp (Hulio)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Aflibercept-Boav (Eydenzelt)
Protein medicineApproved in the United States (FDA)Expanded record